Overview

A Trial of Pharmacist Management of Oral Anticoagulation THerapy Versus Enhanced Usual CARe in the communitY for AF

Status:
Not yet recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

This is a prospective, open-label, cluster-randomized controlled trial of 380 participants (aged 65 years or older, with additional stroke risk factors and 'actionable' undertreated AF) from a total of 38 retail and outpatient community pharmacies. Participants will be randomized (by pharmacy) to either to an intervention arm of pharmacist-led OAC management versus an enhanced usual care arm, wherein physicians receive notification of 'actionable' AF and patients are advised to schedule a physician clinic visit. The primary objective will be to determine the difference in proportion of patients with 'actionable AF' receiving guideline concordant OAC therapy at 3 months in those randomized to intervention arm versus control arm.

Phase:

Phase 4

Details

Lead Sponsor:

Cedars-Sinai Medical Center

Treatments:

Anticoagulants
Warfarin